These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 13129490)

  • 21. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a Phase II study.
    Salah-Eldin MA; Wahba HA; Halim AA
    Indian J Cancer; 2012; 49(1):169-75. PubMed ID: 22842184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
    Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RMA; Anderegg MC; van Oijen MGH; van Laarhoven HWM
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27576566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
    Herzog TJ
    Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Promising new drugs for gynecological cancer].
    Yakushiji M; Sugiyama T; Ushijima K
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1932-7. PubMed ID: 9350238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic therapy for ovarian cancer: current status and new treatments.
    Ozols RF
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies.
    Vasey PA
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S23-8. PubMed ID: 14661043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
    Vach W; Bergmann TK; Brøsen K
    J Clin Oncol; 2008 Apr; 26(11):1903-4; author reply 1904-5. PubMed ID: 18398158
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of topotecan in the treatment of advanced cervical cancer.
    Fiorica JV
    Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S16-21. PubMed ID: 13129491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?
    Flynn PM; Paul J; Cruickshank DJ;
    Gynecol Oncol; 2002 Sep; 86(3):354-7. PubMed ID: 12217760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
    Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
    Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
    Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
    Seung SK; Ross HJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Innovative therapies for advanced ovarian cancer.
    Trimble EL
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):24-30. PubMed ID: 10952123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study.
    Lim MC; Kang S; Choi J; Song YJ; Park S; Seo SS; Park SY
    Ann Surg Oncol; 2009 Apr; 16(4):993-1000. PubMed ID: 19169758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
    Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
    Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.